



## Sight Sciences to Present at the Upcoming 23rd Annual Needham Healthcare Conference

March 26, 2024

MENLO PARK, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced it will present at the upcoming 23<sup>rd</sup> Annual Needham Healthcare Conference being held virtually.

Sight Sciences' management is scheduled to present on Tuesday, April 9, 2024, at 12:45 pm PT / 3:45 pm ET. Interested parties may access a live and archived webcast of the fireside chat on the "Investors" section of the company's website at: [investors.sightsciences.com](https://investors.sightsciences.com).

### About Sight Sciences

Sight Sciences is an eyecare technology company focused on developing and commercializing innovative and interventional technologies intended to transform care and improve patients' lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world's most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company's OMNI® Surgical System is an implant-free glaucoma surgery technology (i) indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and (ii) CE Marked for the catheterization and transluminal viscodilation of Schlemm's canal and the cutting of trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma. Glaucoma is the world's leading cause of irreversible blindness. The Company's TearCare® System technology is 510(k) cleared in the United States for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction ("MGD") when used in conjunction with manual expression of the meibomian glands, enabling clearance of gland obstructions by physicians to address the leading cause of dry eye disease. The Company's SION® Surgical Instrument is a manually operated device available in the United States to be used in ophthalmic surgical procedures to excise trabecular meshwork.

For more information, visit [investors.sightsciences.com](https://investors.sightsciences.com).

Sight Sciences and TearCare are trademarks of Sight Sciences registered in the United States. OMNI, OMNI ERGO, and SION are trademarks of Sight Sciences registered in the United States, European Union and other territories.

© 2024 Sight Sciences. All rights reserved.

### Media contact:

[pr@SightSciences.com](mailto:pr@SightSciences.com)

### Investor contact:

Philip Taylor

Gilmartin Group

415.937.5406

[Investor.Relations@Sightsciences.com](mailto:Investor.Relations@Sightsciences.com)